Imunon (NASDAQ:IMNN) Posts Earnings Results, Beats Estimates By $0.13 EPS

Imunon (NASDAQ:IMNN) issued its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.13, Zacks reports.

Imunon Trading Up 3.2 %

IMNN traded up $0.03 during midday trading on Thursday, hitting $0.83. The company’s stock had a trading volume of 243,272 shares, compared to its average volume of 164,930. Imunon has a 52-week low of $0.64 and a 52-week high of $3.65. The firm has a 50-day moving average price of $0.89 and a two-hundred day moving average price of $0.95. The firm has a market cap of $12.04 million, a P/E ratio of -0.44 and a beta of 2.03.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. D. Boral Capital restated a “buy” rating and issued a $29.00 target price on shares of Imunon in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Imunon in a research report on Thursday, December 19th.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.